Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 227 in previously untreated advanced or recurrent non-small cell lung cancer
NL-OMON47766Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival in PD-L1 expressers and Progression-free survival in high tumor mutation burden population. Started Mar 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47766.